A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Seagen Inc.
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
Kortuc, Inc.
M.D. Anderson Cancer Center
City of Hope Medical Center
City of Hope Medical Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Toray Industries, Inc
Eli Lilly and Company
University Hospital, Geneva
EMD Serono
National Cancer Institute (NCI)
Emory University
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Northwell Health
Ruhr University of Bochum
University of California, San Diego
National Cancer Institute (NCI)
Ruijin Hospital
Gustave Roussy, Cancer Campus, Grand Paris
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
AstraZeneca
Canadian Cancer Trials Group
Abramson Cancer Center at Penn Medicine
National Cancer Institute (NCI)
GOG Foundation
Critical Outcome Technologies Inc.
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
GOG Foundation
OHSU Knight Cancer Institute
ARCAGY/ GINECO GROUP
University of Miami
NewVac LLC
University of Arizona
City of Hope Medical Center
University of Miami
GOG Foundation
GOG Foundation
GOG Foundation
GOG Foundation
GOG Foundation
GOG Foundation
City of Hope Medical Center
Accelerated Community Oncology Research Network